Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8296 to 8310 of 8804 results

  1. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  2. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

    Technology appraisal guidance
    Discontinued

  3. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

    Technology appraisal guidance
    Discontinued

  4. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

    Technology appraisal guidance
    Discontinued

  5. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued Reference number: GID-TA10722

    Technology appraisal guidance
    Discontinued

  6. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued Reference number: GID-TAG280

    Technology appraisal guidance
    Discontinued

  7. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

    Technology appraisal guidance
    Discontinued

  8. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued Reference number: GID-TAG419

    Technology appraisal guidance
    Discontinued

  9. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  10. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

    Technology appraisal guidance
    Discontinued

  11. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  12. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  13. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

    Technology appraisal guidance
    Discontinued

  14. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued Reference number: GID-TA10927

    Technology appraisal guidance
    Discontinued

  15. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development